Testosterone Therapy Appears Safe for Prostate Cancer Patients with Hormone Deficiency, Study Says

Testosterone Therapy Appears Safe for Prostate Cancer Patients with Hormone Deficiency, Study Says
Testosterone therapy appears to be safe for hypogonadal, or testosterone deficient, men with prostate cancer, according to the results of a study conducted at the University of British Columbia in Vancouver, Canada. The study, “Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes,” published in The Journal of Urology, shows that testosterone therapy does not increase the cancer's aggressiveness in these men. Late-onset male hypogonadism occurs in about 3.1 percent to 7 percent of men younger than age 70, and 18.4 percent of men older than 70 years. It is characterized by low levels of testosterone and a constellation of symptoms and physical changes that increase with the degree of deficiency. With earlier detection and improved survival from early stage prostate cancer, it is likely that the numbers of men presenting with hypogonadal symptoms following curative surgery0 will increase. Testosterone therapy (TT), which typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets, has been proven effective in improving symptoms of hypogonadism. But due to claims that testosterone may increase prostate cancer growth, this therapy has been approached with caution in patients. In this study, researchers examined the effects of testosterone therapy in a cohort of people either treated for prostate cancer or on active surveillance for a low-risk cancer. Examining elect
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *